Amalyte and Meiji Seika Kaisha, Ltd. Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds

Published: Jun 08, 2009

SAN FRANCISCO--(BUSINESS WIRE)--Amalyte Pharmaceuticals LLC (Amalyte), a member of the Kemin group of companies, has announced today it has entered into a worldwide strategic alliance with Meiji Seika Kaisha Ltd. (Meiji) to discover, develop and commercialize a lead compound, ME3301 (now AM3301), and novel class of dual-acting anti-inflammatory compounds for a variety of human health applications.

Back to news